Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HSK3486 vs propofol for general anesthesia induction
NCT05478174Phase 3Completed
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Start
- Jul 2022
- Primary completion
- Nov 2023
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of cycloprofol (2 arms), sponsored by Haisco Pharmaceutical Group Co., Ltd. Primary endpoint: Success Rate of General Anesthesia Induction up to 5 minutes. Started Jul 2022; status: completed.
02
Drugs
cycloprofol
Beyond the preview
Go deeper on NCT05478174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05478174.